Karyopharm Therapeutics (KPTI) stock gains as lead drug selinexor (Xpovio) succeeds in a Phase 3 trial for blood cancer ...

Despite failing to achieve one of the co-primary endpoints of the SENTRY study, Karyopharm will still approach the FDA for its sNDA.

Karyopharm is hoping to broaden the label for its first-in-class blood cancer therapy Xpovio to include myelofibrosis, even ...

Myelofibrosis morbidity is driven by splenomegaly, systemic symptoms, and anemia; discontinuation of JAK inhibitors exceeds ...

Xpovio combined with Incyte’s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst’s ...

By Puyaan Singh and Sahil Pandey March 24 (Reuters) - Karyopharm Therapeutics said on Tuesday its therapy led to significant reduction in spleen size in a late-stage study of patients with a rare ...

Results from the phase 3 SENTRY trial show that selinexor plus ruxolitinib significantly reduced spleen volume in patients with myelofibrosis.

March 24 (Reuters) - Karyopharm Therapeutics said on Tuesday its therapy for patients with a rare blood cancer showed a ...

LOS ANGELES, Calif. (Ivanhoe Newswire) - Your blood accounts for about eight percent of your total body weight. It’s vital for life, but when cancer happens in the blood, it can become life-altering ...

Myelofibrosis remains a rare disease, even though recent attention to the condition might suggest otherwise. "I suspect that the incidence is actually higher than what we originally thought, not only ...

Up until fairly recently, ruxolitinib (Jakafi) was the only FDA-approved treatment for intermediate- and high-risk myelofibrosis, and thus has been the cornerstone of myelofibrosis treatment for more ...